查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1861845

依給藥途徑、銷售管道、品牌類型、劑型、最終用戶、通路和藥物類別分類的消化性潰瘍藥物市場－2025-2032年全球預測

Peptic Ulcer Drugs Market by Route Of Administration, Sales Channel, Brand Type, Dosage Form, End User, Distribution Channel, Drug Class - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，消化性潰瘍治療市場將成長至 72 億美元，複合年成長率為 5.38%。

關鍵市場統計數據
基準年 2024 47.3億美元
預計年份：2025年 49.9億美元
預測年份 2032 72億美元
複合年成長率 (%) 5.38%

簡要概述當前影響消化性潰瘍治療格局和相關人員決策的臨床、商業性和供應方面趨勢。

消化性潰瘍藥物治療仍然是胃腸病學實踐的基石，其臨床重點在於控制症狀、促進黏膜癒合和預防併發症。抑酸藥物的進步和臨床流程的改進重塑了消化性潰瘍的診斷和治療，使許多治療決策從住院治療轉移到門診和居家照護護理。患者和醫護人員現在對幽門螺旋桿菌的作用、長期持續抑酸治療的影響以及在慢性治療中平衡療效和安全性的必要性有了更深入的了解。

臨床上，質子幫浦阻斷劑已成為實現強效且持久抑酸的主要治療方法，而H2受體拮抗劑在特定情況下或作為短期治療仍發揮輔助作用。治療格局受到監管措施、產品召回以及不斷變化的非處方藥（OTC）獲取模式的影響，這些因素共同影響處方醫生的行為和患者的自我管理。同時，從原料藥生產到成品藥製造、分銷和臨床應用，藥品供應鏈正變得日益複雜，受到全球採購、監管協調和不斷變化的醫保報銷制度的影響。

本執行摘要總結了影響消化性潰瘍治療領域的當前趨勢，重點闡述了臨床證據、監管動態、商業化管道和營運實際情況之間的相互作用。其目標是為決策者提供清晰、可操作的觀點，將治療效果考量與商業性和供應方面的實際情況相結合，從而支持產品系列、分銷網路和相關人員參與計劃等方面的明智戰略發展。

科學進步、監管力度加大以及通路創新如何推動消化性潰瘍藥物治療路徑的策略性重塑

消化性潰瘍藥物的治療和商業性格局正經歷著一場變革，其驅動力包括科學進步、監管調整以及患者用藥途徑的轉變。在科學方面，對胃酸生理和黏膜保護機制的深入了解，正在改善何時以及如何進行積極的抑酸治療，從而推動指南的修訂和處方實踐的最佳化。同時，真實世界安全性數據和藥物警戒資訊促使人們更加關注長期治療，從而催生出更為謹慎的劑量遞減方案和以合理療程和監測為優先的共同決策工具。

監管和品質方面的挑戰也在推動變革。生產誠信、原料藥採購慣例以及污染事件等問題促使監管力道加大，供應商透明度也受到重視。這些壓力正在加速推動產業採用更完善的品質保證措施和雙重籌資策略，以保障供應的連續性。在商業性，處方藥和非處方藥界限的模糊化擴大了患者的選擇範圍，同時也迫使生產商和經銷商調整其行銷、包裝和患者教育策略，以適應更以零售為導向的環境。

最後，數位技術和分銷創新正在重新定義病患接觸點。遠端醫療後續觀察、遠距藥局服務和線上藥局平台的興起，正在改變患者接受治療的地點和方式，為將持續照護和臨床決策支援工具融入護理流程創造了機會。這些變化迫使現有企業重新定位其產品，增加對品質和合規性的投入，並設計能夠反映全新患者體驗和支付方優先事項的全通路策略。

評估近期消化性潰瘍藥物生產和分銷關稅變化如何推動供應鏈重組、近岸外包和一體化商業策略

近期影響醫藥原料和成品的關稅措施和貿易政策調整，對整個產業的供應鏈經濟和籌資策略帶來了壓力。某些進口藥用原料藥和輔料關稅的提高，迫使生產商重新評估其採購基礎，許多生產商都在權衡更高的到岸成本與供應商突然變更帶來的營運風險。進口關稅也會影響下游決策，例如契約製造合作夥伴的選擇、庫存佈局以及多區域生產結構的永續性。

從營運層面來看，關稅正在加速近岸外包和在地化生產策略的採用，旨在降低跨境關稅和運輸波動帶來的風險。這些轉變通常需要對生產能力和品質系統進行資本投資，這可能會延長新產品上市的前置作業時間。對於依賴複雜全球供應鏈的公司而言，關稅促使它們進行更完善的情境規劃、對供應商生態系統進行壓力測試，並加強圍繞價格和供應連續性的合約保護。

在商業層面，關稅加劇了成本壓力，影響定價策略、與支付方的談判以及銷售管道的獎勵。支付方和採購團隊越來越關注總體擁有成本 (TCO)，其中包括物流成本、關稅負擔和監管合規費用。為此，製造商和經銷商正在探索基本契約、批量採購協議和聯合採購夥伴關係，以確保供貨管道暢通並控制利潤空間。這些調整凸顯了採取綜合性商業策略和供應鏈規劃方法的必要性，以便預測和管理關稅的影響，並在可能的情況下將其轉化為競爭優勢。

深度細分觀點，將給藥途徑、銷售管道、品牌類型、劑型、最終用戶、通路和藥物類別等因素與策略選擇聯繫起來。

細分市場層面的差異揭示了臨床應用、商業策略和營運需求的重要區別，從而影響產品的開發、行銷和交付方式。給藥途徑將市場分類為口服療法（主要用於常規治療和非處方藥）和腸外療法（主要用於急性住院治療和有口服障礙的患者）。銷售管道的不同也帶來了不同的上市要求：非處方藥優先考慮消費者通訊、包裝和零售分銷，而處方藥則需要與處方醫生合作、進行藥品上市談判以及開展藥物監測項目。

品牌類型是策略差異化的新維度。品牌產品在差異化、臨床證據和服務（例如病患支援計畫）方面競爭，而學名藥主要在成本競爭力、生產規模和分銷效率方面競爭。劑型在營運和商業性都至關重要。膠囊、注射和片劑的生產流程、穩定性考量和患者接受度各不相同，這會影響產品生命週期規劃。終端用戶細分進一步決定了部署選擇。居家醫療優先考慮便利性、簡化的給藥方案和病患教育工具；醫院需要注射劑和靜脈注射製劑以及強大的供應物流；而門診診所則需要在成本、依從性和給藥便捷性之間取得平衡。

分銷通路的特徵同樣重要。醫院藥局與住院病患的工作流程和臨床管治緊密結合；線上藥局優先考慮數位互動、合規性和末端物流；而零售藥局則著重於貨架陳列、促銷活動和銷售點諮詢。最後，藥物類別的特徵也對臨床和商業策略都至關重要。 H2受體拮抗劑和質子幫浦阻斷劑在起效速度、效力和作用持續時間方面存在差異，而亞類和具體分子——例如西咪替丁、法莫替丁、尼扎替丁、雷尼替丁、埃索美拉Esomeprazole、蘭索拉唑、奧美拉唑、泮托拉唑和Rabeprazole——則表現出不同的藥代動力學特性和安全性。這些因素會影響處方指南、標籤策略和競爭定位。了解這些多層次細分市場的動態對於使研發重點、生產投資和市場推廣工作與患者照護的實際情況和支付方的期望保持一致至關重要。

美洲、歐洲、中東和非洲以及亞太地區的區域監管、報銷和供應鏈現狀正在塑造差異化的市場進入和商業化策略。

區域趨勢影響法規結構、報銷標準和供應鏈結構，進而對策略規劃產生重大影響。在美洲，監管機構和支付者強調循證處方處方集、成本控制機制以及公私合作採購模式，並評估已證實的臨床價值和成本效益。這種環境鼓勵製造商投資穩健的臨床項目、真實世界證據的生成以及與支付方的合作策略，以在預算限制下平衡療效。

歐洲、中東和非洲地區（EMEA）監管能力和報銷政策的多樣性要求企業制定複雜的打入市場策略。歐洲市場的特點是集中化或統一的核准流程和嚴格的衛生技術評估（HTA），而中東和北非（MENA）市場則呈現出採購模式多樣化、臨床基礎設施差異以及各地監管文件要求不一的局面。製造商和經銷商必須制定符合當地監管要求和採購習慣的授權策略、定價策略和供應鏈方案。

亞太地區呈現出高所得市場快速接受創新以及新興經濟體對高容量、成本敏感的需求並存的局面。該地區的政策制定者日益重視本地製造能力和藥品自給自足，這正在影響外國製造商的市場進入策略和夥伴關係模式。在所有地區，數位化分銷和遠端醫療的普及正在改變患者的就醫模式，因此需要製定區域性數位化互動和電子商務策略，以提升客戶體驗並維持良好的用藥依從性。

決定製造商、學名藥製造商、契約製造製造商、經銷商和服務合作夥伴競爭優勢的策略行動和能力。

為了保持競爭力，消化性潰瘍治療領域的相關人員必須在創新、品質和規模之間取得平衡。大型跨國製藥公司往往投資於廣泛的臨床開發項目、完善的藥物監測基礎設施以及全球製造地，以支持品牌藥和非專利的生產。這些公司優先考慮提高監管多樣性、建立策略聯盟以及應對複雜競標環境的能力，尤其是在醫院採購和國家處方集發揮關鍵作用的情況下。

學名藥和專科藥生產商專注於卓越的生產製造和成本優勢，利用大規模生產和流程最佳化在價格和供應方面競爭。契約製造組織 (CMO) 和活性原料藥(API) 供應商在維持供應連續性方面發揮核心作用，尤其是在企業採取多元化籌資策略以降低品質和地緣政治風險的情況下。經銷商和連鎖藥局（包括線上平台）透過整合物流、進行病患教育舉措和使用數位化互動工具，在影響病患用藥途徑和用藥依從性方面發揮著至關重要的作用。

在這個生態系統中，提供監管協助、品質保證審核和低溫運輸物流等服務供應商透過加快產品上市速度和減輕製造商的營運負擔，創造了策略價值。商業機構與醫院、專科診所等臨床相關人員之間的合作日益普遍，因為這些合作有助於產品進入處方集、收集真實世界證據，並進行上市後監測活動，進而提升產品定位和健保報銷談判的有效性。

提升供應鏈韌性、監管準備和全通路商業化能力，以維持消化性潰瘍治療領域競爭優勢的實用策略

為了把握機會、降低風險，在不斷變化的消化性潰瘍藥物市場中，產業領導者應優先考慮供應鏈韌性、監管靈活性和差異化的病人參與。加強供應商多元化策略，投資區域生產和雙重採購安排，將有助於保障關鍵劑型的持續供應，同時降低貿易中斷和關稅波動帶來的風險。此外，透過實施先進的供應商監控分析方法、加強批次級可追溯性以及主動評估污染風險，實現品質監控現代化，有助於維護產品完整性並符合監管要求。

在商業化過程中，必須針對非處方藥和處方藥市場的不同特點，設計客製化的全通路策略。這包括為居家患者提供數位支援和用藥依從性指導，為醫院和門診醫生提供有針對性的臨床合作，以及最佳化零售和線上分銷模式，以平衡便利性和依從性。價值驗證活動應側重於真實世界的療效、安全性以及對整體醫療成本的影響，以符合支付方的優先事項並支持藥物被納入醫保目錄。

最後，經營團隊應將監理情報分析和情境規劃納入策略決策。積極主動掌握監管趨勢、及早與監管機構溝通以及投資於上市後監測系統，將有助於在出現安全訊號或政策變化時，迅速調整標籤和供應鏈。將業務永續營運、商業性精準性和監管前瞻性結合，不僅能幫助企業抵禦市場衝擊，還能幫助企業打造穩固的競爭優勢。

檢驗済み知見を裏付けるため、一次専門家関与、二次規制,臨床分析、サプライチェーンマッピングを組み合わせた厳密な混合研究手法フレームワークを採用

本分析採用多方法研究策略，結合一手訪談、二手文獻綜述以及結構化的供應鏈和監管分析，以確保研究結果的平衡性和檢驗。我們邀請了來自臨床實踐、藥品生產、分銷和採購領域的專家，收集他們對治療管理、品質和生產挑戰以及商業性需求的多元觀點。此外，我們也利用了包括同儕審查的臨床文獻、監管建議、產業指導文件和公開文件在內的二手資料，以權威證據支持臨床和政策的觀察。

我們的供應鏈評估是基於供應商分佈圖、公開的海關和貿易數據檢驗以及物流路線分析，識別出通用的脆弱性因素和相應的緩解措施。我們的監管分析利用官方機構通訊、安全警報和指導文件，追蹤不斷變化的合規要求和報告義務。在整個研究過程中，我們透過對來自不同獨立資訊來源的研究結果進行三角驗證，以檢驗我們的結論並識別不確定性領域。

本調查方法的一個限制在於，它依賴公開的監管通訊和專家訪談，而這些資料可能無法涵蓋獨特的商業性安排或當前供應商的保密談判。為了彌補這些局限性，本研究提供了透明的假設，並在適用情況下引用了監管觀點，同時鼓勵尋求詳細專有資訊或客製化情境建模的機構進行額外的初步研究。

摘要強調，韌性、證據產生和以客戶為中心的執行是消化性潰瘍藥物領域持續表現的基礎。

消化性潰瘍藥物市場具有持續的臨床需求、不斷加強的監管以及不斷演變的商業性模式等特點，所有這些都要求行業相關人員採取適應性策略。在臨床方面，將有效的抑酸治療與感染控制相結合仍然是重中之重，而安全性考量和患者偏好正在重塑長期用藥方案。在營運方面，供應鏈的韌性和合規性是市場持續性和品牌聲譽的核心決定因素。

商業性成功將越來越依賴以下能力：將產品系列與差異化的患者體驗相匹配；向支付方證明產品的實際價值；以及實施能夠抵禦地緣政治和貿易衝擊的靈活生產和採購模式。積極投資於品質保證、全通路病人參與和監管情報的機構，將更有能力將臨床療效轉化為永續的市場進入和商業性成果。這些結論指向一個以韌性、實證和以客戶為中心的執行為基礎的策略藍圖。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 幽門螺旋桿菌菌株對抗生素抗藥性的日益增強，推動了對新型根除療法的需求。
  • 由於已開發市場廣泛使用非專利PPI，價格競爭日益加劇
  • 開發緩釋性藥物遞送系統以提高消化性潰瘍治療的依從性
  • 增加對細胞保護胜肽類似物作為下一代潰瘍治療藥物的投資
  • 拓展基於患者基因譜和微生物基因組學的個人化治療策略
  • 受消費者對草藥療法的偏好日益成長的推動，天然和植物來源的抗潰瘍化合物的需求激增。
  • 關於長期使用質子幫浦抑制劑的監管建議正在重塑處方實踐和患者管理指南。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按給藥途徑分類的消化性潰瘍藥物市場

  • 口服
  • 腸外

9. 消化性潰瘍藥物市場依銷售管道分類

  • 非處方藥
  • 處方藥

第10章 按品牌類型分類的消化性潰瘍藥物市場

  • 品牌產品
  • 學名藥

第11章 按劑型分類的消化性潰瘍治療市場

  • 膠囊
  • 注射
  • 藥片

第12章 消化性潰瘍藥物市場（依最終用戶分類）

  • 居家醫療
  • 醫院
  • 門診部

第13章 消化性潰瘍藥物市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

14. 消化性潰瘍藥物市場（依藥物類別分類）

  • H2受體拮抗劑
    • 西咪替丁
    • 法莫替丁
    • 尼扎替丁
    • 雷尼替丁
  • 質子幫浦阻斷劑
    • Esomeprazole
    • 蘭索拉唑
    • 奧美拉唑
    • 泮托拉唑
    • Rabeprazole

第15章 各地區消化性潰瘍藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 消化性潰瘍藥物市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 各國消化性潰瘍藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • AstraZeneca plc
    • Takeda Pharmaceutical Company Limited
    • Eisai Co., Ltd.
    • Pfizer Inc.
    • Johnson & Johnson
    • Sanofi SA
    • GlaxoSmithKline plc
    • Bayer AG
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd
Product Code: MRR-2A0283E25692

The Peptic Ulcer Drugs Market is projected to grow by USD 7.20 billion at a CAGR of 5.38% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.73 billion
Estimated Year [2025] USD 4.99 billion
Forecast Year [2032] USD 7.20 billion
CAGR (%) 5.38%

A concise orientation to current clinical, commercial, and supply-side dynamics shaping the peptic ulcer therapeutics environment and stakeholder decisions

Peptic ulcer therapeutics remain a cornerstone of gastroenterology practice, with a clinical focus that spans symptom control, mucosal healing, and complication prevention. Advances in acid suppression pharmacology and refined clinical pathways have reshaped how clinicians diagnose and manage peptic ulcer disease, shifting many care decisions from inpatient settings to ambulatory and home care environments. Patients and providers now benefit from a deeper understanding of Helicobacter pylori's role, the long-term implications of sustained acid suppression, and the need to balance efficacy with safety in chronic therapy.

Clinically, proton pump inhibitors have become the dominant modality for achieving profound and durable acid suppression, while H2 receptor antagonists continue to play a supporting role in selected scenarios and as short-term therapies. The therapeutic landscape has been influenced by regulatory actions, product recalls, and evolving OTC access models, which together affect prescriber behavior and patient self-management. Concurrently, the supply chain that brings these medicines from API production through finished-dose manufacturing to distribution and point-of-care has become more complex, influenced by global sourcing, regulatory harmonization, and evolving reimbursement practices.

This executive summary synthesizes current dynamics affecting the peptic ulcer drugs arena, emphasizing the interplay between clinical evidence, regulatory developments, commercialization channels, and operational realities. The aim is to provide decision-makers with a clear, actionable perspective that integrates therapeutic performance considerations with commercial and supply-side realities, supporting informed strategy development across product portfolios, distribution networks, and stakeholder engagement plans.

How scientific advances, regulatory scrutiny, and distribution innovation are driving a strategic reconfiguration of peptic ulcer therapeutics across care pathways

The therapeutic and commercial landscape for peptic ulcer drugs is undergoing transformative shifts driven by scientific advances, regulatory recalibration, and changes in patient access pathways. On the scientific front, improved mechanistic understanding of gastric acid physiology and mucosal protection has refined when and how aggressive acid suppression is deployed, prompting guideline revisions and more nuanced prescribing practices. At the same time, real-world safety data and pharmacovigilance findings have increased scrutiny of long-term therapy, leading to more deliberate deprescribing frameworks and shared decision-making tools that prioritize appropriate duration and monitoring.

Regulatory and quality challenges have also catalyzed change. Manufactured product integrity, API sourcing practices, and contamination incidents have led to tighter oversight and an emphasis on supplier transparency. These pressures are accelerating industry adoption of enhanced quality assurance measures and dual-sourcing strategies to protect continuity of supply. Commercially, the lines between prescription and over-the-counter access have blurred, expanding patient choice while forcing manufacturers and distributors to adapt marketing, packaging, and patient education efforts to a more retail-oriented context.

Lastly, digital and distribution innovations are redefining patient touchpoints. Telemedicine follow-ups, remote pharmacy services, and the growth of online pharmacy platforms have shifted where and how patients obtain therapies, creating opportunities to embed adherence support and clinical decision aids into the care continuum. Together, these shifts are compelling incumbent players to revisit product positioning, invest in quality and regulatory compliance, and design omnichannel strategies that reflect new patient journeys and payer priorities.

Assessing how recent tariff shifts are prompting supply chain redesign, nearshoring, and integrated commercial strategies across peptic ulcer drug production and distribution

Recent tariff actions and trade policy adjustments affecting pharmaceutical inputs and finished products are exerting pressure on supply chain economics and sourcing strategies across the industry. Increased duties on certain imported active pharmaceutical ingredients and excipients have prompted manufacturers to reassess their procurement footprints, with many evaluating the trade-offs between higher landed costs and the operational risks of rapid supplier substitution. Import tariffs can also influence downstream decisions about contract manufacturing partner selection, inventory positioning, and the viability of maintaining decentralized production across multiple jurisdictions.

From an operational viewpoint, tariffs have accelerated the adoption of nearshoring and regional manufacturing strategies aimed at mitigating exposure to cross-border duties and transport volatility. These shifts often require capital investment in manufacturing capacity and quality systems, and they can extend lead times for new product introductions. For companies that rely heavily on complex global supply chains, tariffs have encouraged the development of more robust scenario planning and stress-testing of supplier ecosystems, as well as stronger contractual protections around pricing and supply continuity.

On the commercial side, tariff-driven cost pressures are influencing pricing strategies, negotiations with payers, and channel incentives. Payers and procurement teams are increasingly attentive to total cost of ownership, which includes logistics, tariff burden, and regulatory compliance overhead. In response, manufacturers and distributors are exploring value-based contracting, bundled procurement arrangements, and collaborative sourcing partnerships to preserve access while managing margin compression. These adaptive measures underscore the need for integrated commercial and supply chain planning to ensure that tariff impacts are anticipated, managed, and, where possible, converted into competitive advantage.

Deep segmentation perspectives that connect administration routes, sales channels, brand types, dosage forms, end users, distribution channels, and drug classes to strategic choices

Segment-level distinctions reveal meaningful differences in clinical use, commercial strategy, and operational requirements that shape how products are developed, marketed, and delivered. Route of administration divides the landscape between oral therapies, which dominate routine management and OTC access, and parenteral options that are reserved for acute hospital care or patients unable to tolerate oral dosing. Sales channels create divergent go-to-market imperatives: over-the-counter availability prioritizes consumer-facing messaging, packaging, and retail distribution, while prescription drugs require prescriber engagement, formulary access negotiations, and pharmacovigilance programs.

Brand type introduces another axis of strategic differentiation. Branded products often compete on differentiation, clinical evidence, and service offerings such as patient support programs, whereas generics compete primarily on cost competitiveness, manufacturing scale, and distribution efficiency. Dosage form matters operationally and commercially; capsules, injections, and tablets each entail distinct manufacturing processes, stability considerations, and patient acceptance dynamics that influence product lifecycle planning. End-user segmentation further informs deployment choices, with home care favoring convenience, simplified regimens, and patient education tools, hospitals requiring injectable and IV-compatible formulations alongside robust supply logistics, and outpatient clinics balancing cost, adherence, and ease of administration.

Distribution channel nuances are equally consequential. Hospital pharmacies maintain tight integration with inpatient workflows and clinical governance, online pharmacies prioritize digital engagement, compliance, and last-mile logistics, and retail pharmacies emphasize shelf placement, promotional activity, and point-of-sale counseling. Finally, drug class characteristics underpin both clinical and commercial strategy. H2 receptor antagonists and proton pump inhibitors differ in onset, potency, and duration of effect, with subclasses and individual molecules such as cimetidine, famotidine, nizatidine, ranitidine, esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole exhibiting distinct pharmacokinetic and safety profiles that inform prescribing guidance, labeling strategies, and competitor positioning. Understanding these layered segmentation dynamics is essential for aligning R&D priorities, manufacturing investments, and market access efforts with the realities of patient care and payer expectations.

Regional regulatory, reimbursement, and supply chain realities across the Americas, EMEA, and Asia-Pacific that shape differentiated market entry and commercialization approaches

Regional dynamics shape regulatory frameworks, reimbursement norms, and supply chain architectures in ways that materially affect strategic planning. In the Americas, regulatory authorities and payer systems emphasize evidence-based formularies, cost containment mechanisms, and a mix of public and private procurement approaches that reward demonstrated clinical value and cost-effectiveness. This environment incentivizes manufacturers to invest in robust clinical programs, real-world evidence generation, and payer engagement strategies that reconcile therapeutic benefits with budgetary constraints.

In Europe, the Middle East, and Africa, heterogeneity in regulatory capacity and reimbursement policies requires nuanced market entry strategies. European markets often feature centralized or harmonized approval pathways coupled with stringent HTA processes, while markets in the Middle East and Africa present a mosaic of procurement models, varying levels of clinical infrastructure, and differing demands for local regulatory documentation. Manufacturers and distributors must therefore tailor their licensing, pricing, and supply chain approaches to reflect local regulatory expectations and procurement behaviors.

The Asia-Pacific region presents a blend of rapid innovation adoption in some high-income markets and large-volume, cost-sensitive demand in emerging economies. Policymakers in the region have increasingly prioritized local manufacturing capacity and pharmaceutical self-sufficiency, which affects foreign manufacturers' market access strategies and partnership models. Across all regions, digital distribution and telehealth adoption are changing patient access patterns, necessitating region-specific digital engagement and e-commerce strategies to capture new customer journeys and preserve adherence outcomes.

Strategic behaviors and capabilities of manufacturers, generics producers, contract manufacturers, distributors, and service partners that determine competitive positioning

Industry players operating in the peptic ulcer therapeutics space must balance innovation, quality, and scale to remain competitive. Large multinational pharmaceutical firms tend to invest in broad clinical development programs, extensive pharmacovigilance infrastructure, and global manufacturing footprints that support both branded and generic portfolios. These firms prioritize regulatory diversification, strategic alliances, and the ability to navigate complex tendering environments, especially where hospital procurement and national formularies play a pivotal role.

Generic manufacturers and specialty producers focus on manufacturing excellence and cost leadership, leveraging high-volume production and process optimization to compete on price and availability. Contract manufacturing organizations and API suppliers are central to maintaining continuity of supply, particularly as firms pursue multi-sourcing strategies to mitigate quality and geopolitical risks. Distributors and pharmacy chains, including online platforms, play a critical role in shaping patient access and adherence through integrated logistics, patient education initiatives, and digital engagement tools.

Across this ecosystem, service providers that deliver regulatory support, quality assurance auditing, and cold chain logistics add strategic value by reducing time-to-market and lowering the operational burden on manufacturers. Partnerships between commercial organizations and clinical stakeholders-such as hospitals and specialty clinics-are increasingly common, as these collaborations facilitate formulary access, real-world evidence collection, and post-launch surveillance activities that reinforce product positioning and reimbursement negotiations.

Actionable strategies for strengthening supply resilience, regulatory readiness, and omnichannel commercialization to sustain competitive advantage in peptic ulcer therapeutics

Industry leaders should prioritize supply chain resilience, regulatory agility, and differentiated patient engagement to capture opportunities and mitigate risks in the evolving peptic ulcer therapeutics landscape. Strengthening supplier diversification strategies and investing in regional manufacturing or dual-sourcing arrangements will reduce vulnerability to trade disruptions and tariff volatility while supporting continuity of supply for critical dosage forms. Concurrently, companies should modernize quality oversight by implementing advanced analytics for supplier monitoring, enhanced lot-level traceability, and proactive contamination risk assessment to preserve product integrity and regulatory compliance.

On commercialization, organizations must design tailored omnichannel strategies that reflect the distinct dynamics of over-the-counter and prescription markets. This includes digital outreach and adherence support for home care patients, targeted clinical engagement for hospital and outpatient clinic prescribers, and optimized retail and online distribution models that address convenience and compliance. Value demonstration efforts should focus on real-world effectiveness, safety profiles, and total cost of care implications to align with payer priorities and to support favorable formulary positioning.

Finally, leaders should embed regulatory intelligence and scenario planning into strategic decision-making. Anticipatory regulatory mapping, early dialogue with authorities, and investment in post-market surveillance infrastructure will accelerate responsive labeling and supply adjustments when safety signals or policy shifts occur. By integrating operational resilience, commercial precision, and regulatory foresight, companies can not only withstand market disruptions but also create defensible competitive advantages.

A rigorous mixed-method research framework combining primary expert engagement, secondary regulatory and clinical analysis, and supply chain mapping to underpin validated insights

This analysis was developed using a multi-method research approach that combined primary interviews, secondary literature review, and structured supply chain and regulatory analysis to ensure balanced and validated insights. Subject-matter experts from clinical practice, pharmaceutical manufacturing, distribution, and procurement were consulted to capture diverse perspectives on therapeutic management, quality and manufacturing challenges, and commercial imperatives. Secondary sources included peer-reviewed clinical literature, regulatory advisories, industry guidance documents, and public filings to ground clinical and policy observations in authoritative evidence.

Supply chain assessments relied on supplier mapping, review of public customs and trade data, and analysis of logistics pathways to identify common vulnerabilities and mitigation strategies. Regulatory analysis drew on public agency communications, safety alerts, and guidance documents to track evolving compliance expectations and reporting obligations. Throughout the research process, findings were triangulated across independent sources to validate conclusions and to expose areas of uncertainty.

Limitations of the methodology include reliance on publicly available regulatory communications and expert interviews that may not capture proprietary commercial arrangements or the most recent confidential supplier negotiations. To mitigate these constraints, the study emphasizes transparent assumptions, cites regulatory positions where applicable, and recommends follow-up primary research for organizations seeking deep-dive, proprietary intelligence or custom scenario modeling.

Concluding synthesis emphasizing resilience, evidence generation, and customer-centric execution as pillars for sustained performance in peptic ulcer therapeutics

The peptic ulcer therapeutics arena is characterized by enduring clinical needs, ongoing regulatory vigilance, and evolving commercial modalities that together demand adaptive strategies from industry participants. Clinically, effective acid suppression and the integration of infection management remain priority imperatives, while safety considerations and patient preference are reshaping long-term use. Operationally, supply chain robustness and regulatory compliance are central determinants of market continuity and brand reputation.

Commercial success will increasingly depend on the ability to align product portfolios with differentiated patient journeys, to demonstrate real-world value to payers, and to deploy flexible manufacturing and sourcing models that withstand geopolitical and trade-related shocks. Organizations that proactively invest in quality assurance, omnichannel patient engagement, and regulatory intelligence will be best positioned to translate clinical efficacy into sustainable market access and commercial performance. These conclusions point toward a strategic roadmap built on resilience, evidence, and customer-centric execution.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing antibiotic resistance in H. pylori strains driving demand for novel eradication therapies
  • 5.2. Growing uptake of generic proton pump inhibitors leading to intensified price competition in developed markets
  • 5.3. Development of sustained-release drug delivery systems to enhance peptic ulcer treatment adherence
  • 5.4. Rising investment in cytoprotective peptide analogues as next generation ulcer healing agents
  • 5.5. Expansion of personalized therapy strategies based on patient genetic profiling and microbial genomics
  • 5.6. Surge in natural and plant-derived antiulcer compounds spurred by consumer preference for herbal remedies
  • 5.7. Regulatory advisories on long-term PPI use reshaping prescribing practices and patient management guidelines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Peptic Ulcer Drugs Market, by Route Of Administration

  • 8.1. Oral
  • 8.2. Parenteral

9. Peptic Ulcer Drugs Market, by Sales Channel

  • 9.1. Over The Counter
  • 9.2. Prescription Drugs

10. Peptic Ulcer Drugs Market, by Brand Type

  • 10.1. Branded
  • 10.2. Generic

11. Peptic Ulcer Drugs Market, by Dosage Form

  • 11.1. Capsule
  • 11.2. Injection
  • 11.3. Tablet

12. Peptic Ulcer Drugs Market, by End User

  • 12.1. Home Care
  • 12.2. Hospitals
  • 12.3. Outpatient Clinics

13. Peptic Ulcer Drugs Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Online Pharmacies
  • 13.3. Retail Pharmacies

14. Peptic Ulcer Drugs Market, by Drug Class

  • 14.1. H2 Receptor Antagonists
    • 14.1.1. Cimetidine
    • 14.1.2. Famotidine
    • 14.1.3. Nizatidine
    • 14.1.4. Ranitidine
  • 14.2. Proton Pump Inhibitors
    • 14.2.1. Esomeprazole
    • 14.2.2. Lansoprazole
    • 14.2.3. Omeprazole
    • 14.2.4. Pantoprazole
    • 14.2.5. Rabeprazole

15. Peptic Ulcer Drugs Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Peptic Ulcer Drugs Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Peptic Ulcer Drugs Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. AstraZeneca plc
    • 18.3.2. Takeda Pharmaceutical Company Limited
    • 18.3.3. Eisai Co., Ltd.
    • 18.3.4. Pfizer Inc.
    • 18.3.5. Johnson & Johnson
    • 18.3.6. Sanofi S.A.
    • 18.3.7. GlaxoSmithKline plc
    • 18.3.8. Bayer AG
    • 18.3.9. Novartis AG
    • 18.3.10. Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. PEPTIC ULCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. PEPTIC ULCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PEPTIC ULCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CIMETIDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CIMETIDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CIMETIDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CIMETIDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CIMETIDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CIMETIDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY FAMOTIDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY FAMOTIDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY FAMOTIDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY FAMOTIDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY FAMOTIDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY FAMOTIDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY NIZATIDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY NIZATIDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY NIZATIDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY NIZATIDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY NIZATIDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY NIZATIDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RANITIDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RANITIDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RANITIDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RANITIDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RANITIDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RANITIDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OMEPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OMEPRAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OMEPRAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OMEPRAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OMEPRAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OMEPRAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PANTOPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PANTOPRAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PANTOPRAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PANTOPRAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PANTOPRAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PANTOPRAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RABEPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RABEPRAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RABEPRAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RABEPRAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RABEPRAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RABEPRAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 305. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 310. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 315. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 316. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 317. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 318. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 319. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 320. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 324. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 325. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 326. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 327. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. ASIA-PACIFIC PEPTIC UL